Clinical trials open for the enrollment


Title: KRT232-117 – “An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With a Tyrosine Kinase Inhibitor (TKI) in Patients With Relapsed or Refractory Ph+ Chronic Myeloid Leukemia (CML)”

 

Study aimed to investigating the efficacy of KRT-232, an inhibitor of the MDM2 oncogene (which in turn inhibits the p53 tumor suppressor), in combination with a tyrosine kinase inhibitor normally used in Ph+ cronic myeloid leukemia.

 

Principal Investigator: Prof. Pierfrancesco Tassone

 

For enrollment information please contact: Dr. Luigia Gervasi (Tel: +39 0961-3647921) Email: luigiagervasi@gmail.com


Title: innovaTV207 – “Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors”

 

In this trial are investigated efficacy and safety of tisotumab vedotin, antbody- drugconjugate direct against tissutal factor, alone or in association with other drugs, in following neoplasms: colorectal, non-small cell lung cancer, exocrine pancrea, head and neck.

 

Principal Investigator: Prof. Pierfrancesco Tassone

 

For enrollment information please contact: Dr. Luigia Gervasi (Tel: 0961-3647921) Email: luigiagervasi@gmail.com


Title: CA043-001 – An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers

 

Phase 1/2 first-in-human trial that investigates role of BMS-986288 (a modified form of ipilimumab), alone or in association to nivolumab, in various tumors.

 

Principal Investigator: Prof. Pierfrancesco Tassone

 

For enrollment information please contact: Dr. Luigia Gervasi (Tel: 0961-3647921) Email: luigiagervasi@gmail.com

 


Clinical trials closed for the enrollment

Title: LNA-i-miR-221 – “A dose escalation phase I study of LNA-i-miR-221 for the treatment of refractory multiple myeloma and advanced solid tumors”

Sponsor: Azienda Ospedaliero-Universitaria Mater Domini Catanzaro – Studio Clinico di Fase I spontaneo supportato da progetto AIRC 5×1000

Principal Investigator: Prof. Pierfrancesco Tassone

Download PDF Protocollo v 2.0

Download PDF Protocollo v3.0